



Diabetes of the Exocrine Pancreas Related to Hereditary Pancreatitis, an Update

Gabriel Xavier Ramalho¹ · Marcio Garrison Dytz^{1,2,3,4}

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Abstract

Purpose of Review The aim was to review evidence about diabetes secondary to hereditary pancreatitis, seeking novel diagnostic and treatment features.

Recent Findings Hereditary pancreatitis (HP) is an autosomal dominant condition, characterized by recurrent episodes of acute pancreatitis, progression to fibrosis, and chronic pancreatitis. Clinical presentation includes diabetes of the exocrine pancreas (DEP). HP prevalence ranges from 0.3 to 0.57 per 100,000 people, with up to 80% of these develop DEP. This condition often requires specific interventions: with regard to metabolic control, metformin is the first choice for those with mild DEP, and for those in advanced disease, insulin is considered the first-line therapy. Insulin analogues and insulin pump therapy are preferred due to the brittle glycemic pattern and risk of hypoglycemia. In case of exocrine insufficiency, pancreatic enzyme replacement therapy is recommended. Pancreatic polypeptide administration is a promising novel treatment feature.

Summary DEP due to HP appears to be a misdiagnosed condition. The requirement of specific management demonstrates the importance of this matter; therefore, appropriate recognition and classification are important.

Keywords Hereditary pancreatitis · Diabetes of the exocrine pancreas · Brittle diabetes · PRSS1 · SPINK1

Introduction

Hereditary pancreatitis (HP) is an autosomal dominant condition, with an estimated penetrance of 80%. It is a rare disease characterized by recurrent episodes of acute pancreatitis, progression to fibrosis, and chronic pancreatitis (CP) [1••]. The first HP report was in 1952 by Comfort and Steinberg, who suggested a genetic background [2].

It was only in 1996 that an associated genetic mutation, R122H, was identified by Whitcomb et al. in the cationic trypsinogen gene (PRSS1) [3]. In the following years, several PRSS1 mutations and diverse HP related genes were discovered, specifically the serine protease inhibitor Kazal type 1 (SPINK1), the cystic fibrosis transmembrane conductance regulator (CFTR), the chymotrypsin C (CTRC) [4–7], and the carboxypeptidase A1 (CPA1) [4, 8].

The clinical presentation of HP includes abdominal pain, malabsorptive syndrome due to pancreatic exocrine dysfunction, and diabetes mellitus (DM) due to islet cell damage [9]. Diabetes mellitus caused by exocrine insufficiency used to be called by pancreatogenic DM or type 3c diabetes (T3cDM) [10] notwithstanding more recently the medical literature refers to it as diabetes of the exocrine pancreas (DEP) [11]. DEP encompasses diverse causes with CP the most common, although pancreatic ductal adenocarcinoma and cystic fibrosis are equally of importance [12].

Diabetes is an independent risk factor of mortality in these patients, with micro and macrovascular damage caused by DEP being a significant late sequelae of CP [13]. While the prevalence of DM is estimated to be 9.3% in the US general

✉ Marcio Garrison Dytz
marcio.dytz@ceub.edu.br

Gabriel Xavier Ramalho
gxramalho@hotmail.com

¹ School of Medicine, Faculty of Education and Health Sciences, University Center of Brasilia (UniCEUB), Brasilia, Brazil

² Endocrinology Division, Department of Intern Medicine, Sobradinho Regional Hospital, Brasilia, Brazil

³ Endocrinology and Metabolism Medical Residency, Superior School of Health Sciences (ESCS), Brasilia, Brazil

⁴ Institute of Diabetes and Endocrinology of Brasilia, SHS Qd. 6 Cj. A Bl. E Sl 1119, Brasilia, DF 70316-902, Brazil

population [14], in CP patients it is up to about 80% [14, 15], which demonstrates the importance of this matter.

Therefore, this article aims to review the literature on DEP and its relationship to hereditary pancreatitis.

Epidemiology

There is currently insufficient data to precisely estimate the prevalence of DEP due to HP [15, 16]. In addition to the small number of studies performed in this condition, DEP is also underestimated and underdiagnosed, making estimation of worldwide prevalence challenging [17].

Chronic pancreatitis is a major cause of DEP (25–80%) [18, 19] with an incidence of 9.62 cases per 100,000 person-years [20]. Due to the difficulty in diagnosing CP, the prevalence of CP has been conservatively estimated to be as high as 120–143 per 100,000 individuals [21]. Adopting cohorts with diabetes to estimate DEP prevalence, it is acceptable to assume that this ranges from 5 to 10% in a population of individuals with diabetes [12]. Moreover, HP is an underestimated cause of CP, with up to 32% of idiopathic chronic pancreatitis having underlying genetic mutations [22]. HP has an estimated prevalence that varies greatly depending on the region, between 0.3 to 0.57 per 100,000 according to national cohort data [22, 23].

Analyzing several HP regional studies, there are significant variation in epidemiological data. The discrepancy is more notable in PRSS1 mutation percentage, which ranges from 10.5 to 67.5, and is directly influenced by the different clinical criteria used to determine genetic testing. The lack of a uniform diagnostic criteria leads to heterogeneous samples and may also explain discordant diabetes rates, median time to DEP, and cumulative risk of DM found in these series (Table 1).

Genetics

Since 1996, when the first genetic association was described, more than 35 mutations of PRSS1 were discovered [30, 31]. This autosomal-dominant gene mutation pattern, found in 65–100% of hereditary pancreatitis kindreds [16], is associated with an increase of autocatalytic conversion of trypsinogen to active trypsin (Fig. 1) [32]. This abnormal intrapancreatic process is responsible for the progressive destruction of acinar cells, resulting in ductal and interstitial injury [4]. The most common PRSS1 mutations (R122H and N29I) are those associated with gain of function, responsible for enhancing trypsinogen autoactivation, and increasing trypsin stability [33, 34].

In contrast, SPINK1 is responsible for controlling intra pancreatic trypsin 1 activity, revealing itself as the first line of defense against this abnormal conversion. It represents a loss of function mutation with a recessive inheritance pattern that results in a decreased trypsin degradation [35]. Facing SPINK1's inheritance model, in which less than 1% of the carriers develop CP, it was proposed a complex pathophysiology participation of gene-environment and gene-gene interactions [36]. These genetic mutations build a high-risk model that might help explain disparate CP susceptibilities in alcoholic and tropical pancreatitis diseases [36, 37].


Other genetic defects are also involved, such as CTRC, which is responsible for all human trypsin and trypsinogen degradation [38], yet CTRC mutation appears to be a low-risk factor [6]. In other hand, CFTR may cause cystic fibrosis in severe mutation cases [39]; it is also a loss function gene, reducing bicarbonate conductance [40]. A number of distinct genes have recently been related to HP: CPA1 due to endoplasmic reticulum stress [41], CTSB due to a suppositional premature trypsin activation [42], and CLDN2 and CASR which pathological implications are currently unknown [43, 44].

Table 1 Epidemiological and clinical data based on HP regional series

Author/year of publication	Region	No. of patients	HP prevalence/100,000	PRSS1 Mutation (%)	Diabetes (%)	Median time to DEP (years)	Cumulative risk of DM at 50 years (%)
Applebaum-Shapiro et al/2001 [24]	USA	717	–	67	–	–	–
Keim et al/2001 [25]	Germany	550	–	18.4	24	–	–
Howes et al/2004* [1]	Europe	527	–	81	32	53	47.6
Masamune et al/2017 [26]	Japan	271	0.35	41	21.6	58	36
Rebours et al/2008 [23]	France	200	0.3	67.5	26	38	–
Joergensen et al/2010 [22]	Denmark	122	0.57	14.8	32	–	–
Räty et al/2007 [27]	Finland	36	–	22	0	–	–
Palaez-Luna et al/2014 [28]	Mexico	19	–	10.5	5	–	–
Dytz et al/2015 [29]	Brazil	16	–	62.5	31.3	–	–

*On behalf of the European Registry of Hereditary Pancreatitis and Pancreatic Cancer (EUROPAC)

Fig. 1 Schematic mechanism underlying mutations associated with pancreatitis. ER, endoplasmic reticulum. Use authorized by Dytz et al., 2015 [29]



Pathophysiology

Chronic pancreatitis is marked by recurrent acute episodes inducing severe damage to the endocrine and exocrine parenchyma, which may lead to their respective pancreatic insufficiencies [45]. An inflammatory pattern is observed in all types of events which induce exocrine injuries, causing increased intracellular levels of activated pancreatic enzymes. In the long term, there is an ongoing damage to the pancreas via oxidative stress [46].

Exocrine insufficiency due to progression of inflammatory and fibrotic processes occurs in up to 37% of the patients with HP at 50 years of age [1••] and owing to the large pancreatic reserve available; pancreatic exocrine insufficiency only occurs when more than 90% of exocrine function is lost [47]. Malabsorptive syndrome is one of the most important HP’s clinical repercussion, and it is also significantly associated with a higher mortality [48].

Endocrine insufficiency is observed in up to 47% of the patients with HP at 50 years and 79% at 80 years [1••]. Although continuous damage to the islet cells is parallel with the exocrine degradation, overt diabetes occurs later in DEP [49]. The DEP’s pathology basis is endogenous insulin deficiency, due to initially an inflammatory environment and β -cells dysfunction, followed by significant β -cells loss caused by progressive fibrosis [50••].

Aside from β -cells loss, there is also fundamental α -cells dysfunction resulting in counter regulatory hormone deficiency. Lack of glucagon counter-regulatory response is a significant contributor to glycemic lability, and variability frequently observed in these patients [50••]. Lack of coordinated digestion and absorption, diminished paracrine, and endocrine

factors as well as impaired activation of hepatic gluconeogenesis are other mechanisms also associated to the brittle diabetes glycemic patterns pathophysiology [17]. Hypoglycemic excursions in the context of increased glycemic variability is a major clinical endpoint of the aforementioned mechanisms and is an important risk factor of increased mortality [51••].

Deficiency of pancreatic polypeptide (PP) response may also play a key role in hepatic insulin resistance [52]. PP is a glucoregulatory hormone that regulates the expression of insulin receptors which modulate hepatic insulin sensitivity response [53]. Therefore, DEP appears to also be an independent risk factor contributing to increased peripheral insulin resistance and diabetes [54].

Clinical Aspects

HP is distinguished by an early age of onset; the primary manifestation is usually acute pancreatitis at 10–12 years [1••, 23], although in some studies the median age was even earlier [55, 56]. The evolution to exocrine insufficiency mostly occurs at second or third decade of life, when epigastric abdominal pain becomes the most common symptom, which might be followed by exocrine pancreatic insufficiency syndrome including abdominal cramps, fatty stools associated with steatorrhea, and malnutrition [57].

The overall median onset age of DEP due to HP is estimated to be 53 years [1••]; paradoxically, DEP can sometimes be the primary presentation of HP [58]. Its duration does not appear to be influenced by mutation status or gender [1••, 26]. Notwithstanding, DEP is generally reported as a brittle disease; there is a lack of data about rates of hypoglycemia in

DEP [18••, 58]. Available data suggest that episodic non-severe hypoglycemia occurs in up to 79% of patients with pancreatogenic diabetes, and severe hypoglycemia occurs in up to 41% [59]. The reported increased risk of hypoglycemia is associated with increased mortality [60].

There are also exiguous data about metabolic control in DEP especially due to HP [15]. A Brazilian cohort study demonstrated high rates of hypoglycemia and capillary blood glucose variability in patients with DM associated with HP [61]. Another study compared glycemic variability (GV) between DEP and T2DM, with higher GV and rates of hyperglycemia observed in the DEP group [62]. Even with high glucose levels, these patients rarely present ketoacidosis, probably because of the remaining β -cells function, in which absolute insulin deficiency is uncommon [63, 64].

Diagnosis

Diabetes mellitus in the context of disease of the exocrine pancreas is not commonly recognized by physicians; its diagnosis might be challenging, specially due to a lack of definitive criteria, what should be the explanation of the fact that the most cases are initially misdiagnosed as T2DM. Edwald and Bretzel propose the following criteria for DEP secondary to CP (Table 2) [18••]:

These criteria might be helpful, however, have been criticized for the laboriousness of applying them to all clinical settings [65]. For the American Diabetes Association (ADA) recommendations, there are no specific diagnostic criteria for DEP. Even though, the use of the above mentioned major criteria is encouraged by the association as a distinguishing feature [11].

The most commonly used criteria for HP was defined by European Registry of Hereditary Pancreatitis and Pancreatic Cancer (EUROPAC) trial and is made on basis of two first-degree relatives, or three or more second-degree relatives, in two or more generations with recurrent acute pancreatitis and/or CP, for which there were no predisposing factors [1••].

Once HP diagnosis is made, diabetes (or prediabetes) screening might be performed annually with random glucose, HbA1c, and/or oral glucose tolerance test (OGTT) [50••, 58]. This investigation is crucial since it is observed a substantial increase in diabetes prevalence with longer duration of HP [66].

Despite the DEP diagnostic proposal criteria, in usual clinical practice, DM patients who present with malabsorptive syndrome associated to episodes of acute pancreatitis and a glycemic brittleness hard to control should raise clinical suspicions of DEP. A history of recurrent unexplained attacks of acute pancreatitis, unexplained chronic pancreatitis episode with or without a positive family history, as a well as CP episodes in children should instigate investigation for HP, mainly in DM patients. Thus, more studies are needed to define clinical and characteristic features with reasonable sensitivity and specificity for diagnosis of DEP related to HP.

Management

DEP often requires specific interventions [67]. As insulin deficiency is a key pathophysiological feature of DEP, insulin is considered first line therapy for most patients with advanced disease [68]. The initial dose calculation of insulin therapy should follow those on multiple daily injections (MDI) in T1DM [50••]. Despite of the side effects, such increasing risk of pancreatic cancer, with an odds ratio of 2.78 and hazard ratio of cancer-related mortality of 1.9 ($p < 0.05$) [69, 70], insulin remains the preferred treatment especially during acute episodes of pancreatitis as well in hospitalized and malnourished patients, in which the anabolic insulin effects are desired [50••].

Insulin therapy presents a risk of hypoglycemia notably for those with an increased peripheral insulin sensitivity [71]. The labile glycemic control is the reason why glucose levels should be slightly upward the normal targets, as HbA1c $< 7\%$, aiming to improve the quality of life [72, 73]. Providing DM structured education programs is important to achieve target glycemic control and to allow flexibility in dietary

Table 2 Diagnostic criteria for DEP secondary to CP

Major criteria (all must be present)
• A diagnosis of diabetes mellitus.
• Evidence of exocrine pancreatic insufficiency (according to the monoclonal fecal elastase-1 test or direct function tests).
• Pathological pancreatic imaging (endoscopic ultrasound, magnetic resonance imaging, or computed tomography).
• Absence of type 1 diabetes mellitus associated autoimmune markers.
Minor criteria
• Impaired beta cell function (e.g., HOMA-B, C-peptide/glucose-ratio).
• No excessive insulin resistance (e.g., HOMA-IR).
• Impaired incretin secretion (e.g. GLP-1, pancreatic polypeptide).
• Low serum levels of lipid soluble vitamins (A, D, E, and K).

intake [74]. These planned and graded process should facilitate the knowledge, skills, and ability for diabetes self-management by enhancing health-promoting behaviors and empower people with DM to implement flexible intensive insulin therapy [75].

Some treatment approaches may also be considered aiming to reduce the risk of hypoglycemia, such the insulin analogues and insulin pump therapy [50••, 61]. Recently, the use of the real-time continuous glucose monitoring (RT-CGM) for people with type 1 diabetes treated with MDI have been shown to be effective in improving glycemic control and reducing the risk of hypoglycemia [76]. RT-CGM might represent a change management approach for patients with problematic hypoglycemia, such DEP patients, since markedly improves HbA1C and glycemic variability indices, as well as reduces the number of hypoglycemic excursions. It is reasonable that RT-CGM benefits can be extended to DEP patients treated with MDI, representing high clinical relevance, especially for those who are unable to use insulin pumps [77].

Additional features may be held intending to improve the metabolic control of these patients. Coefficient of variation (CV), considered the main acceptable measure of glycemic variability, and standard deviation (SD) have been commonly used as glycemic variability indices. Both CV and SD are obtained using continuous glucose monitoring measures. These are robust features which use should improve glycemic control while avoiding hypoglycemia [78]. Their clinical application is supported by the fact that HbA1c is a poor predictor of hypoglycemic episodes, specially the silent ones, whereas low GV represents trustingly a low risk of severe hypoglycemia [79, 80].

In those with mild severity of DM (HbA1c < 8%), oral hypoglycemic agents might be considered [50••]. Metformin should be the first choice; besides of the convenience of using an oral agent, this drug offers a theoretical anti-neoplastic effect, decreasing the risk of pancreatic ductal adenocarcinoma [69, 81]. Nevertheless, it also causes weight loss and important gastrointestinal adverse effects that need to be tolerated [50••]. A second-line therapy is the thiazolidinediones (TZD); these drugs appear to improve the hepatic and peripheral insulin sensitivities in experimental studies [82]. However, TZD should only be recommended considering the possible impact of their side effects, especially the risk of fracture and congestive heart failure [83].

Incretin-based therapies, including glucagon-like peptide-1 (GLP-1) analogues and oral dipeptidyl peptidase-4 inhibitors, are not commonly recommended. Notwithstanding enhancing insulin secretion, these drugs are associated with a hypothetical increased risk of drug-induced pancreatitis and pancreatic cancer [84]. In the same way, sodium-glucose cotransporter 2 inhibitors (SGLT2) should be avoided due to the lack of data in this context, as well as the important side effects such risk of dehydration and weight loss [85].

The primary medical nutrition therapy goals should include preventing or treating malnutrition, controlling symptoms of steatorrhea, and minimizing meal induced hyperglycemia [50••]. In case of exocrine insufficiency of any degree to prescribe pancreatic enzyme replacement therapy (PERT) is recommended. This replacement aims to increase postprandial response, enable the absorption of vitamin D, and to prevent A, D, E, and K vitamins deficiency [86]. PERT and vitamin D replacement are critical to prevent metabolic bone disease and osteoporosis in these patients [87].

DEP glucose levels are usually reported as difficult to control. Facing this struggle, PP administration reveals itself as a promising novel feature. Several studies showed that PP therapy reversed the hepatic insulin resistance, enabled effective utilization of circulating insulin, and improved glycemic control, decreasing insulin requirements in DEP patients [52, 88–90]. Whether it is available, a semester screening of pancreatic polypeptide response might be helpful, if reduced would assist in early identification of impaired pancreatic endocrine function, and consequent increased risk of diabetes in HP patients with CP [91].

Moreover, total pancreatectomy with islet autotransplantation (TPIAT) might be an option in patients with severe complications, suffering refractory abdominal pain, or in those with high risk of pancreatic cancer. This endocrine function-preserving autologous islet cell isolation and re-implantation method cannot be considered a prevention nor a treatment for diabetes. The primary objective of this surgical approach is the pain relieving [51••]. Therefore, in selected patients, TPIAT has been shown to be effective in restoring the quality of life, as well as improving the glycemic control [92].

Complications

DM and CP are both independent risk factors for pancreatic ductal adenocarcinoma; therefore, there is no doubt that this combination, present in people with DEP, represents a significant increased risk of developing this type of cancer [93]. Moreover, it was estimated a 35% lifetime risk of developing pancreatic cancer for patients with HP notably those bearing the R122H mutation [94]. Screening HP patients for pancreatic cancer has been advocated and should be performed with pancreatic magnetic resonance imaging and/or endoscopic ultrasound in experienced centers. This surveillance should be initiated at age [50] years or 10 years younger than the earliest age of pancreatic cancer in the family [95]. Furthermore, in HP symptomatic patients, genetic testing is justified aiming to clarify etiology and provide genetic counseling [16].

DEP appears to share a similar risk for the micro and macro-vascular complications observed in T1DM [66]. This risk is diminished by a good glycemic control. GV, higher in DEP than in type 2 diabetes, is considered an independent risk

for these complications [96]. Further studies are needed to endorse the association with higher rates of vascular complications. Therefore, these patients should be monitored following the same guidelines proposed for type 1 and 2 DM [50••].

Conclusion

In summary, this study contributes to the characterization of diabetes mellitus in the context of disease of the exocrine pancreas related to hereditary pancreatitis. Nevertheless, more surveys are required to establish practicable clinical diagnostic criteria, as the lack of this feature carries us into a mis- and underdiagnosing scenario. A clinical suspicion of DEP due to HP should instigate investigation, since the correct diagnosis allows an effective assistance of these patients, recommending precise and needed treatments as well as preventing severe complications. Furthermore, we believe that this article has high clinical relevance, seeing that reviews HP endocrine outcomes and detailing novel diagnostic and treatment features about the theme.

Author Contributions Both authors wrote the manuscript and contributed to the design, drafting, and reviewing the paper.

Funding Information No specific grant was received from any funding agency in the public, commercial, or not-for-profit sector for the publication of this report.

Compliance with Ethical Standards

Conflict of Interest The authors declare that they have no conflicts of interest.

Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as:

•• Of major importance

1. Howes N, Lerch MM, Greenhalf W, Stocken DD, Ellis I, Simon P, et al. Clinical and genetic characteristics of hereditary pancreatitis in Europe. *Clin Gastroenterol Hepatol*. 2004;2:252–61 **It is one of the most robust HP regional series and presented an estimated HP prevalence, cumulative risk of DEP as also the diagnostic criteria of HP used in our study.**
2. Comfort MW, Steinberg AG. Pedigree of a family with hereditary chronic relapsing pancreatitis. *Gastroenterology*. 1952;54–63. [https://doi.org/10.1016/s0016-5085\(52\)80120-9](https://doi.org/10.1016/s0016-5085(52)80120-9).
3. Whitcomb DC, Gorry MC, Preston RA, Furey W, Sossenheimer MJ, Ulrich CD, et al. Hereditary pancreatitis is caused by a mutation

- in the cationic trypsinogen gene. *Nat Genet*. 1996;141–5. <https://doi.org/10.1038/ng1096-141>.
4. Whitcomb DC, et al. *Gastroenterology*. 2013;1292–302. <https://doi.org/10.1053/j.gastro.2013.01.069>.
5. Shelton CA, Whitcomb DC. Genetics and treatment options for recurrent acute and chronic pancreatitis. *Curr Treat Options Gastroenterol*. 2014;12:359–71.
6. Rosendahl J, Landt O, Bernadova J, Kovacs P, Teich N, Bödeker H, et al. CFTR, SPINK1, CTRC and PRSS1 variants in chronic pancreatitis: is the role of mutated CFTR overestimated? *Gut*. 2013; 582–92. <https://doi.org/10.1136/gutjnl-2011-300645>.
7. Chen J-M, Férec C. Genetics and pathogenesis of chronic pancreatitis: The 2012 update. *Clin Res Hepatol Gastroenterol*. 2012;334–40. <https://doi.org/10.1016/j.clinre.2012.05.003>.
8. Whitcomb DC, Alzheimer's Disease Genetics Consortium, LaRusch J, Krasinskas AM, Klei L, Smith JP, et al. Common genetic variants in the CLDN2 and PRSS1-PRSS2 loci alter risk for alcohol-related and sporadic pancreatitis. *Nat Genet*. 2012;1349–54. <https://doi.org/10.1038/ng.2466>.
9. Rosendahl J, Bödeker H, Mössner J, Teich N. *Orphanet J Rare Dis*. 2007;1. <https://doi.org/10.1186/1750-1172-2-1> <http://ojrd.biomedcentral.com/articles/10.1186/1750-1172-2-1>.
10. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. *Diabetes Care*. 2003;26(Suppl 1): S5–20.
11. American Diabetes Association. 2. Classification and diagnosis of diabetes: diabetes care. 2020;43:S14–31.
12. Ewald N, Kaufmann C, Raspe A, Kloer HU, Bretzel RG, Hardt PD. Prevalence of diabetes mellitus secondary to pancreatic diseases (type 3c). *Diabetes Metab Res Rev*. 2012;28:338–42.
13. Seicean A, Tantău M, Grigorescu M, Mocan T, Seicean R, Pop T. Mortality risk factors in chronic pancreatitis. *J Gastrointest Liver Dis*. 2006;15:21–6.
14. Xu G, Liu B, Sun Y, Du Y, Snetselaar LG, Hu FB, et al. Prevalence of diagnosed type 1 and type 2 diabetes among US adults in 2016 and 2017: population based study. *BMJ*. 2018;362:k1497.
15. Hart PA, Bellin MD, Andersen DK, Bradley D, Cruz-Monserrate Z, Forsmark CE, et al. Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer. *Lancet Gastroenterol Hepatol*. 2016;1:226–37.
16. Shelton C, Whitcomb DC. Hereditary chronic pancreatitis. *Pancreas*. 2018;374–83. <https://doi.org/10.1002/9781119188421.ch45>.
17. Hardt PD, Brendel MD, Kloer HU, Bretzel RG. Is pancreatic diabetes (type 3c diabetes) underdiagnosed and misdiagnosed? *Diabetes Care*. 2008;31(Suppl 2):S165–9.
18. Ewald N, Bretzel RG. Diabetes mellitus secondary to pancreatic diseases (Type 3c) — are we neglecting an important disease? *European Journal of Internal Med*. 2013;203–6. <https://doi.org/10.1016/j.ejim.2012.12.017> **This study proposed a diagnostic criteria for DEP secondary to HP, intending to fill the absence of a precise classification.**
19. Malka D, Hammel P, Sauvanet A, Rufat P, O'Toole D, Bardet P, et al. Risk factors for diabetes mellitus in chronic pancreatitis. *Gastroenterology*. 2000;1324–32. <https://doi.org/10.1053/gast.2000.19286>.
20. Xiao AY, Tan MLY, Wu LM, Asrani VM, Windsor JA, Yadav D, et al. Global incidence and mortality of pancreatic diseases: a systematic review, meta-analysis, and meta-regression of population-based cohort studies. *Lancet Gastroenterol Hepatol*. 2016;1:45–55.
21. Lévy P, Domínguez-Muñoz E, Imrie C, Löhr M, Maisonneuve P. Epidemiology of chronic pancreatitis: burden of the disease and consequences. *United European Gastroenterol J*. 2014;2:345–54.
22. Joergensen MT, Brusgaard K, Crüger DG, Gerdes A-M, de Muckadell OSB. Genetic, epidemiological, and clinical aspects of hereditary pancreatitis: a population-based cohort study in

- Denmark. *Am J Gastroenterol.* 2010;1876–83. <https://doi.org/10.1038/ajg.2010.193>.
23. Rebours V, Boutron-Ruault M-C, Schnee M, Férec C, Le Maréchal C, Hentic O, et al. The natural history of hereditary pancreatitis: a national series. *Gut.* 2009;58:97–103.
 24. Applebaum-Shapiro SE, Finch R, Pfützner RH, Hepp LA, Gates L, Amann S, et al. Hereditary pancreatitis in North America: the Pittsburgh-Midwest Multi-Center Pancreatic Study Group Study. *Pancreatol.* 2001;439–43. <https://doi.org/10.1159/000055844>.
 25. Keim V, Bauer N, Teich N, Simon P, Lerch MM, Mössner J. Clinical characterization of patients with hereditary pancreatitis and mutations in the cationic trypsinogen gene. *Am J Med.* 2001;111:622–6.
 26. Masamune A, Kikuta K, Hamada S, Nakano E, Kume K, Inui A, et al. Nationwide survey of hereditary pancreatitis in Japan. *J Gastroenterol.* 2018;53:152–60.
 27. Rätty S, Piironen A, Babu M, Pelli H, Sand J, Uotila S, et al. Screening for human cationic trypsinogen (PRSS1) and trypsinogen inhibitor gene (SPINK1) mutations in a Finnish family with hereditary pancreatitis. *Scand J Gastroenterol.* 2007;1000–5. <https://doi.org/10.1080/00365520701206738>.
 28. Pelaez-Luna M, Robles-Diaz G, Canizales-Quinteros S, Tusié-Luna MT. PRSS1 and SPINK1 mutations in idiopathic chronic and recurrent acute pancreatitis. *World J Gastroenterol.* 2014;20:11788–92.
 29. Dytz MG, de Melo JM, de Castro Santos O, da Silva Santos ID, Rodacki M, Conceição FL, et al. Hereditary pancreatitis associated with the N29T mutation of the PRSS1 gene in a Brazilian family. *Medicine.* 2015:e1508. <https://doi.org/10.1097/md.0000000000001508>.
 30. Masamune A, Research Committee of Intractable Pancreatic Diseases in Japan, Kikuta K, Nabeshima T, Nakano E, Hirota M, et al. Nationwide epidemiological survey of early chronic pancreatitis in Japan. *Journal of Gastroenterology.* 2017;992–1000. <https://doi.org/10.1007/s00535-017-1311-8>.
 31. Németh BC, Sahin-Tóth M. Human cationic trypsinogen (PRSS1) variants and chronic pancreatitis. *Am J Physiol Gastrointest Liver Physiol.* 2014;306:G466–73.
 32. Sahin-Tóth M, Tóth M. Gain-of-function mutations associated with hereditary pancreatitis enhance autoactivation of human cationic trypsinogen. *Biochem Biophys Res Commun.* 2000;278:286–9.
 33. Sahin-Tóth M. Human cationic trypsinogen. Role of Asn-21 in zymogen activation and implications in hereditary pancreatitis. *J Biol Chem.* 2000;275:22750–5.
 34. Kukor Z, Tóth M, Pál G, Sahin-Tóth M. Human cationic trypsinogen. Arg(117) is the reactive site of an inhibitory surface loop that controls spontaneous zymogen activation. *J Biol Chem.* 2002;277:6111–7.
 35. Witt H, Luck W, Hennies HC, Classen M, Kage A, Lass U, et al. Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis. *Nat Genet.* 2000;25:213–6.
 36. Aoun E, Chang C-CH, Greer JB, Papachristou GI, Barmada MM, Whitcomb DC. Pathways to injury in chronic pancreatitis: decoding the role of the high-risk SPINK1 N34S haplotype using meta-analysis. *PLoS One.* 2008;3:e2003.
 37. Masamune A, Shimosegawa T. Genetics of pancreatitis. *Alcoholic/Non-Alcoholic Digestive Diseases.* 2019. 139–49. https://doi.org/10.1007/978-981-13-1465-0_12
 38. Szmola R, Sahin-Toth M. Chymotrypsin C (caldecrin) promotes degradation of human cationic trypsin: identity with Rinderknecht's enzyme Y. *Proc Natl Acad Sci.* 2007;11227–32. <https://doi.org/10.1073/pnas.0703714104>.
 39. Bombieri C, Claustres M, De Boeck K, Derichs N, Dodge J, Girodon E, et al. Recommendations for the classification of diseases as CFTR-related disorders. *J Cyst Fibros.* 2011;10(Suppl 2):S86–102.
 40. Schneider A, Larusch J, Sun X, Aloe A, Lamb J, Hawes R, et al. Combined bicarbonate conductance-impairing variants in CFTR and SPINK1 variants are associated with chronic pancreatitis in patients without cystic fibrosis. *Gastroenterology.* 2011;140:162–71.
 41. Witt H, Beer S, Rosendahl J, Chen J-M, Chandak GR, Masamune A, et al. Variants in CPA1 are strongly associated with early onset chronic pancreatitis. *Nat Genet.* 2013;45:1216–20.
 42. Mahurkar S, Idris MM, Reddy DN, Bhaskar S, Rao GV, Thomas V, et al. Association of cathepsin B gene polymorphisms with tropical calcific pancreatitis. *Gut.* 2006;55:1270–5.
 43. Felderbauer P, Hoffmann P, Einwächter H, Bulut K, Ansoerge N, Schmitz F, et al. A novel mutation of the calcium sensing receptor gene is associated with chronic pancreatitis in a family with heterozygous SPINK1 mutations. *BMC Gastroenterology.* 2003. <https://doi.org/10.1186/1471-230x-3-34>.
 44. Derikx MH, Kovacs P, Scholz M, Masson E, Chen J-M, Ruffert C, et al. Polymorphisms at PRSS1–PRSS2 and CLDN2–MORC4 loci associate with alcoholic and non-alcoholic chronic pancreatitis in a European replication study. *Gut.* 2015:1426–33. <https://doi.org/10.1136/gutjnl-2014-307453>.
 45. Whitcomb DC, Frulloni L, Garg P, Greer JB, Schneider A, Yadav D, et al. Chronic pancreatitis: an international draft consensus proposal for a new mechanistic definition. *Pancreatol.* 2016;16:218–24.
 46. Sankaran SJ, Xiao AY, Wu LM, Windsor JA, Forsmark CE, Petrov MS. Frequency of progression from acute to chronic pancreatitis and risk factors: a meta-analysis. *Gastroenterology.* 2015:1490–500.e1. <https://doi.org/10.1053/j.gastro.2015.07.066>.
 47. DiMaggio EP, Go VLW, Summerskill WHJ. Relations between pancreatic enzyme outputs and malabsorption in severe pancreatic insufficiency. *N Engl J Med.* 1973;813–5. <https://doi.org/10.1056/nejm197304192881603>.
 48. de la Iglesia-Garcia D, Vallejo-Senra N, Iglesias-Garcia J, López-López A, Nieto L, Domínguez-Muñoz JE. Increased risk of mortality associated with pancreatic exocrine insufficiency in patients with chronic pancreatitis. *J Clin Gastroenterol.* 2018;52:e63–72.
 49. Andersen BN, Nyboe Andersen B, Krarup T, Thorsgaard Pedersen N, Faber OK, Hagen C, et al. B cell function in patients with chronic pancreatitis and its relation to exocrine pancreatic function. *Diabetologia.* 1982;8:6–9. <https://doi.org/10.1007/bf01271165>.
 50. Rickels MR, Bellin M, Toledo FGS, Robertson RP, Andersen DK, Chari ST, et al. Detection, evaluation and treatment of diabetes mellitus in chronic pancreatitis: recommendations from PancreasFest 2012. *Pancreatol.* 2013;13:336–42 **One of the scarce documents that could be used as DEP management recommendations, resulted from specialists consensus with clinical and research expertise.**
 51. Makuc J. Management of pancreatogenic diabetes: challenges and solutions. *Diabetes Metab Syndr Obes.* 2016;9:311–5 **A management review that ensures the importance of nutrition therapy, and the need of more studies for novel promising drugs, such the pancreatic polypeptide.**
 52. Brunicaudi FC. Pancreatic polypeptide administration improves abnormal glucose metabolism in patients with chronic pancreatitis. *J Clin Endocrinol Metabol.* 1996;3566–72. <https://doi.org/10.1210/jc.81.10.3566>.
 53. Seymour NE, Volpert AR, Lee EL, Andersen DK, Hernandez C. Alterations in hepatocyte insulin binding in chronic pancreatitis: effects of pancreatic polypeptide. *Am J Surg.* 1995;169:105–9 discussion 110.
 54. Niebisz-Cieślak AB, Kamafel W. Insulin sensitivity in chronic pancreatitis and features of insulin resistance syndrome. *Pol Arch Med Wewn.* 2010;120:255–63.

55. Sossenheimer MJ, Aston CE, Preston RA, Gates LK Jr, Ulrich CD, Martin SP, et al. Clinical characteristics of hereditary pancreatitis in a large family, based on high-risk haplotype. The Midwest Multicenter Pancreatic Study Group (MMPSG). *Am J Gastroenterol*. 1997;92:1113–6.
56. Gory MC, Gabbazideh D, Furey W, Gates LK Jr, Preston RA, Aston CE, et al. Mutations in the cationic trypsinogen gene are associated with recurrent acute and chronic pancreatitis. *Gastroenterology*. 1997;113:1063–8.
57. Kleinman L, Benjamin K, Viswanathan H, Mattera MS, Bosserman LD, Blayney DW, et al. Development of the anemia impact measure (AIM): a disease-specific patient reported outcome (PRO) instrument to measure anemia symptoms and their impact on functioning in cancer patients receiving chemotherapy. *Blood*. 2008; 668. <https://doi.org/10.1182/blood.v112.11.668.668>.
58. Johnston PC, Thompson J, Mckee A, Hamill C, Wallace I. Diabetes and chronic pancreatitis: considerations in the holistic management of an often neglected disease. *J Diabetes Res*. 2019;2019:2487804.
59. Parsaik AK, Murad MH, Sathananthan A, Moorthy V, Erwin PJ, Chari S, et al. Metabolic and target organ outcomes after total pancreatectomy: Mayo Clinic experience and meta-analysis of the literature. *Clin Endocrinol*. 2010;723–31. <https://doi.org/10.1111/j.1365-2265.2010.03860.x>.
60. Kleeff J, Whitcomb DC, Shimosegawa T, Esposito I, Lerch MM, Gress T, et al. Chronic pancreatitis. *Nat Rev Dis Primers*. 2017;3: 17060.
61. Dytz MG, Marcelino PAH, de Castro Santos O, Zajdenverg L, Conceição FL, Ortiga-Carvalho TM, et al. Clinical aspects of pancreatogenic diabetes secondary to hereditary pancreatitis. *Diabetol Metab Syndr*. 2017;9:4.
62. Shivaprasad C, Aiswarya Y, Kejal S, Sridevi A, Anupam B, Ramdas B, et al. Comparison of CGM-derived measures of glycemic variability between pancreatogenic diabetes and type 2 diabetes mellitus. *J Diabetes Sci Technol*. 2019;1932296819860133.
63. Pancreatogenic (type 3c) diabetes. The Pancreapedia: Exocrine Pancreas Knowledge Base. <https://doi.org/10.3998/panc.2015.35>
64. Sjoberg RJ, Kidd GS. Pancreatic diabetes mellitus. *Diabetes Care*. 1989;715–24. <https://doi.org/10.2337/diacare.12.10.715>.
65. Roeyen G, De Block C. A plea for more practical and clinically applicable criteria defining type 3c diabetes. *Pancreatology*. 2017;17:875.
66. Wang W, Guo Y, Liao Z, Zou D-W, Jin Z-D, Zou D-J, et al. Occurrence of and risk factors for diabetes mellitus in Chinese patients with chronic pancreatitis. *Pancreas*. 2011;40:206–12.
67. Andersen DK, Korc M, Petersen GM, Eibl G, Li D, Rickels MR, et al. Diabetes, pancreatogenic diabetes, and pancreatic cancer. *Diabetes*. 2017;66:1103–10.
68. Ramsey ML, Conwell DL, Hart PA. Complications of chronic pancreatitis. *Dig Dis Sci*. 2017;62:1745–50.
69. Li D, Yeung S-CJ, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies affect risk of pancreatic cancer. *Gastroenterology*. 2009;137:482–8.
70. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. *Diabetes Care*. 2006;254–8. <https://doi.org/10.2337/diacare.29.02.06.de05-1558>.
71. Cui Y, Andersen DK. Pancreatogenic diabetes: special considerations for management. *Pancreatology*. 2011;11:279–94.
72. Andersen DK. The practical importance of recognizing pancreatogenic or type 3c diabetes. *Diabetes Metab Res Rev*. 2012;326–8. <https://doi.org/10.1002/dmrr.2285>.
73. Tiengo A, de Kreutzenberg SV, Del Prato S. Diabetes in pancreatitis, pancreatectomy and other pancreatic diseases. *Front Diabetes*. 2014;119–43. <https://doi.org/10.1159/000357252>.
74. Rankin D, the UK NIHR DAFNE Study Group, Cooke DD, Elliott J, Heller SR, Lawton J. Supporting self-management after attending a structured education programme: a qualitative longitudinal investigation of type 1 diabetes patients' experiences and views. *BMC Public Health*. 2012. <https://doi.org/10.1186/1471-2458-12-652>
75. Reddy M, Rilstone S, Cooper P, Oliver NS. Type 1 diabetes in adults: supporting self management. *BMJ*. 2016;i998. <https://doi.org/10.1136/bmj.i998>.
76. Šoupal J, Petruželková L, Flekač M, Pelcl T, Matoulek M, Daňková M, et al. Comparison of different treatment modalities for type 1 diabetes, including sensor-augmented insulin regimens, in 52 weeks of follow-up: a COMISAIR Study. *Diabetes Technol Ther*. 2016;18:532–538.
77. Heinemann L, Freckmann G, Ehrmann D, Faber-Heinemann G, Guerra S, Waldenmaier D, et al. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. *Lancet*. 2018;391:1367–77.
78. Suh S, Kim JH. Glycemic variability: how do we measure it and why is it important? *Diabetes Metab J*. 2015;39:273–82.
79. Jeha GS, Karaviti LP, Anderson B, O'Brian Smith E, Donaldson S, McGirk TS, et al. Insulin pump therapy in preschool children with type 1 diabetes mellitus improves glycemic control and decreases glucose excursions and the risk of hypoglycemia. *Diabetes Technol Ther*. 2005;876–84. <https://doi.org/10.1089/dia.2005.7.876>.
80. Group TDCACR, The Diabetes Control and Complications Trial Research Group. Hypoglycemia in the diabetes control and complications trial. *Diabetes*. 1997;271–86. <https://doi.org/10.2337/diab.46.2.271>.
81. Wang Z, Lai S-T, Xie L, Zhao J-D, Ma N-Y, Zhu J, et al. Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. *Diabetes Res Clin Pract*. 2014;106:19–26.
82. Zhou X, You S. Rosiglitazone inhibits hepatic insulin resistance induced by chronic pancreatitis and IKK- β /NF- κ B expression in liver. *Pancreas*. 2014;43:1291–8.
83. Kung J, Henry RR. Thiazolidinedione safety. *Expert Opin Drug Saf*. 2012;11:565–79.
84. Forsmark CE. Incretins, diabetes, pancreatitis and pancreatic cancer: what the GI specialist needs to know. *Pancreatology*. 2016;10–3. <https://doi.org/10.1016/j.pan.2015.11.009>.
85. Lin YK, Johnston PC, Arce K, Hatipoglu BA. Chronic pancreatitis and diabetes mellitus. current treatment options in gastroenterology. 2015. p. 319–31. <https://doi.org/10.1007/s11938-015-0055-x>
86. Nikfarjam M, Wilson JS, Smith RC. Diagnosis and management of pancreatic exocrine insufficiency. *Med J Aust*. 2017;161–5. <https://doi.org/10.5694/mja16.00851>.
87. Duggan SN, Ewald N, Kelleher L, Griffin O, Gibney J, Conlon KC. The nutritional management of type 3c (pancreatogenic) diabetes in chronic pancreatitis. *Eur J Clin Nutr*. 2017;71:3–8.
88. Seymour NE, Brunicaudi FC, Chaiken RL, Lebovitz HE, Chance RE, Gingerich RL, et al. Reversal of abnormal glucose production after pancreatic resection by pancreatic polypeptide administration in man. *Surgery*. 1988;104:119–29.
89. Rabiee A, Galiatsatos P, Salas-Carrillo R, Thompson MJ, Andersen DK, Elahi D. Pancreatic polypeptide administration enhances insulin sensitivity and reduces the insulin requirement of patients on insulin pump therapy. *J Diabetes Sci Technol*. 2011;5:1521–8.
90. Hennig R, Kekis PB, Friess H, Adrian TE, Büchler MW. Pancreatic polypeptide in pancreatitis. *Peptides*. 2002. p. 331–8. [https://doi.org/10.1016/s0196-9781\(01\)00605-2](https://doi.org/10.1016/s0196-9781(01)00605-2).
91. Aslam M, Vijayasathary K, Talukdar R, Sasikala M, Nageshwar RD. Reduced pancreatic polypeptide response is associated with early alteration of glycemic control in chronic pancreatitis. *Diabetes Res Clin Pract*. 2019;107993.
92. Bellin MD, Beilman GJ, Sutherland DE, Ali H, Petersen A, Mongin S, et al. How durable is total pancreatectomy and intraportal islet

- cell transplantation for treatment of chronic pancreatitis? *J Am Coll Surg*. 2019;228:329–39.
93. Cui Y, Andersen DK. Diabetes and pancreatic cancer. *Endocr Relat Cancer*. 2012;19:F9–26.
94. Felderbauer P, Stricker I, Schnekenburger J, Bulut K, Chromik AM, Belyaev O, et al. Histopathological features of patients with chronic pancreatitis due to mutations in the PRSS1 gene: evaluation of BRAF and KRAS2 mutations. *Digestion*. 2008;78:60–5.
95. Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. *Am J Gastroenterol*. 2015;223–62. <https://doi.org/10.1038/ajg.2014.435>.
96. Liang S, Yin H, Wei C, Xie L, He H, Liu X. Glucose variability for cardiovascular risk factors in type 2 diabetes: a meta-analysis. *J Diabetes Metab Disord*. 2017. <https://doi.org/10.1186/s40200-017-0323-5>.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.